fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Gilead Sciences to withdraw Trodelvy (sacituzumab govitecan-hziy) for bladder cancer in the US

Written by | 25 Oct 2024

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy (sacituzumab goviteca-hziy) as a bladder cancer treatment in the U.S. Gilead Sciences announced… read more.

Application submitted for third indication of darolutamide in the EU – Bayer

Written by | 19 Oct 2024

Bayer announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use… read more.

Urovant Sciences announced the commercial launch of Gemtesa (vibegron) 75 mg tablets for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults

Written by | 15 Sep 2024

Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has announced the commercial launch of Gemtesa (vibegron) 75 mg tablets, a beta-3… read more.

ChatGPT shows promise in answering patients’ questions to urologists

Written by | 26 Aug 2024

The groundbreaking ChatGPT chatbot shows potential as a time-saving tool for responding to patient questions sent to the urologist’s office, suggests a study in the September issue of Urology… read more.

FDA approval sought for UGN 102 in low-grade, intermediate-risk, non–muscle-invasive, bladder cancer – Urogen Pharma

Written by | 22 Aug 2024

A new drug application (NDA) has been submitted to the FDA seeking the approval of mitomycin for intravesical solution (UGN 102) for the treatment of patients with low-grade,… read more.

At-home colon cancer screening compares well with colonoscopy

Written by | 31 Jul 2024

Researchers report that at-home colon cancer screening could reduce the risk of colorectal cancer death by 33%. The findings were published on July 19, 2024 in JAMA Network… read more.

The Stockholm3 prostate cancer test is effective for diverse ethnic groups and could reduce unnecessary biopsies

Written by | 30 Jul 2024

The Stockholm3 blood test is equally precise at detecting prostate cancer in different ethnic groups, and it could reduce unnecessary biopsies by about half, researchers reported on July… read more.

New medication for stress urinary incontinence? Investigational drug shows promise

Written by | 18 Jul 2024

An investigational medication designated TAS-303 shows efficacy and safety in treatment of women with stress urinary incontinence (SUI), reports a placebo-controlled clinical trial in the August issue of The Journal… read more.

Darolutamide meets primary endpoint in phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer – Bayer + Orion

Written by | 18 Jul 2024

The Phase III ARANOTE trial, investigating darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of rPFS.( radiological progression-free survival). Darolutamide… read more.

European Commission approves Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma – BMS

Written by | 23 Jun 2024

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable… read more.

Offering both colonoscopy and at-home tests doubled colorectal cancer screening

Written by | 19 May 2024

The rate of colorectal cancer screenings more than doubled when patients were given a choice between which type of screening they wanted—a take-home kit or colonoscopy—compared to those… read more.

FDA approves Anktiva, (N-803, or nogapendekin alfa inbakicept-pmln) first-in-class IL-15 receptor agonist for BCG-unresponsive non-muscle invasive bladder cancer – ImmunityBio

Written by | 6 May 2024

ImmunityBio, Inc. an immunotherapy company, announced that the FDA has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.